Unimedic Pharma AB announces distribution and launch of Zeqmelit® orodispersible film (dexametason) in Sweden, Norway, and Finland

Stockholm, September 17^th, 2024 – Unimedic Pharma AB has according to plan started the distribution and launch of Zeqmelit® orodispersible film (dexametason) in Sweden, Norway, and Finland.

As Nordic partner to AcuCort, Unimedic Pharma carry the responsibility for marketing, distribution, and sales of the prescription drug Zeqmelit® (dexametason) in the Nordic region. From September, Zeqmelit® is available for prescription in Sweden, Norway, and Finland.

Johan Frödin, CEO Unimedic Pharma, says: “We are pleased that Zeqmelit® now is available to allergy patients in the Nordic market. We firmly believe that this new, innovative and easy-to-use form of administration will be beneficial for patients in acute allergic situations. Zeqmelit® is a product that fits well into our product range.”

About Zeqmelit® (dexametason)

Zeqmelit®, is an orodispersible film containing the glucocorticoid dexamethasone. Dexamethasone belongs to the group of glucocorticoids, known to reduce inflammation, symptoms of allergic reactions and suppress the immune system. Zeqmelit® is approved for, amongst other indications, allergic reactions including acute allergic reactions, treatment of acute severe asthma, croup in children, nausea and vomiting during chemotherapy, and for the treatment of patients with COVID-19 requiring supplemental oxygen therapy.

About Unimedic Pharma

Unimedic Pharma is a fully integrated Swedish specialty pharma company with broad experience in drug development, distribution, and marketing of pharmaceuticals. Unimedic Pharma supply the Nordic region and northern Europe with a wide range of pharmaceuticals in several therapeutic areas. We are continuously expanding our product portfolio through long-term strategic partnerships, development of proprietary pharmaceuticals and acquisitions of products and companies.

About AcuCort

AcuCort is an innovative biotechnology company that identifies, develops, and commercializes smart drugs that meet the patient’s needs for a user-friendly and effective treatment. Potential drug candidates are based on existing and well-documented substances in indication areas where there is a great medical need and commercial interest in new and innovative products that bring benefits, such as simple administration.